Suggestions

Du même auteur

Three-Year Treatment Outcomes of Aflibercept Versus Ranibizumab for Diabetic Macular Edema: Data from the Fight Retinal Blindness! Registry

Archive ouverte | Gabrielle, Pierre-Henry | CCSD

International audience. PURPOSE: Compare the three-year outcomes of ranibizumab versus aflibercept in eyes with DME in daily practice. METHODS: This was a retrospective analysis of naive DME eyes starting intravitre...

Incidence, risk factors and outcomes of submacular haemorrhage with loss of vision in neovascular age‐related macular degeneration in daily clinical practice: data from the FRB! registry

Archive ouverte | Gabrielle, Pierre‐Henry | CCSD

International audience. PURPOSE: The main purpose of the study was to report the estimated incidence, cumulative rate, risk factors and outcomes of submacular haemorrhage (SMH) with loss of vision in neovascular age...

Can high-dose aflibercept satisfy unmet treatment needs in diabetic macular oedema?

Archive ouverte | Gabrielle, Pierre-Henry | CCSD

Corresponding author: catherine.creuzot-garcher@chu-dijon.fr. International audience. Refers toIntravitreal aflibercept 8 mg in diabetic macular oedema (PHOTON): 48-week results from a randomised, double-masked, non...

Chargement des enrichissements...